ÂÜÀòÂÒÂ×

Josh Bilenker is the co-founder and Chief Executive Officer of Treeline Biosciences. Previously, he was the CEO of Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company. Dr. Bilenker joined Eli Lilly in 2019 after it acquired his prior company, Loxo Oncology, Inc. From 2006 to 2013, Dr. Bilenker worked as a life sciences venture capital investor at Aisling Capital LLC. From 2004 to 2006, Dr. Bilenker served as a medical officer at the US Food and Drug Administration, in the Office of Oncology. Dr. Bilenker trained at the University of Pennsylvania in internal medicine and medical oncology, earning board certification in these specialties. He received his M.D. from The Johns Hopkins University School of Medicine and his A.B. degree in English from Princeton University.